Evidence map›Paper›PMID 33777762›Full record

ArticleFrontiers in oncology2021

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With

Delin Yuan, Genhong Li, Lian Yu, Yuelong Jiang, Yuanfei Shi, Qiulin Chen, Xiaomei Ma, Lan V Pham, Ken H Young, Manman Deng and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Targeting MYC-driven lymphoma: lessons learned and future directions.Cancer drug resistance (Alhambra, Calif.) · 2023
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Delin YuanDepartment of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Genhong LiDepartment of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Lian YuDepartment of Hematology and Rheumatology, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, China.
Yuelong JiangDepartment of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Yuanfei ShiDepartment of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Qiulin ChenDepartment of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Xiaomei MaDepartment of Hematology and Rheumatology, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, China.
Lan V PhamBiology, Tumor Dependency, Phamacyclics, Abbvie Company, San Francisco, CA, United States.
Ken H YoungDivision of Hematopathology, Department of Pathology, Duke University Medical Center, Duke University, Durham, NC, United States.
Manman DengDepartment of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Zhihong FangDepartment of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Bing XuDepartment of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
First Affiliated Hospital of Xiamen University · CNFirst Affiliated Hospital of Fujian Medical University · CNDuke University Hospital · USPharmacyclics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade B-cell lymphoma with concurrent

Indexed as

BCL2combination therapyCS2164HGBL-DHLMYCPI3K signalingsynergy/synergismvenetoclax

Identifiers

PMID33777762
PMCPMC7988232
OpenAlexW3135196497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.